VRC-01
Based on 1 Customer Validation
VRC-01 is a broadly neutralizing IgG1 monoclonal antibody that targets HIV-1 envelope glycoprotein gp120 Protein. VRC-01 blocks HIV-1 viral entry by mimicking CD4 receptor interaction with HIV-1 gp120 and neutralizes broad HIV-1 clades. VRC-01 can be used for the research of HIV-1 infection.
For research use only. We do not sell to patients.
- Purity: 99.805%
- CAS No.: 1412901-55-3
- Molecular Weight:145.87 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Human IgG1 kappa
Human
|
HIV-1 |
VRC-01 binds HIV-1 gp120 IIIB with Kd values of 1.68 nM and 1.39 nM for transient and stable tobacco plant-produced VRC-01, respectively[2].
VRC-01 (1-24 h) from transient and stable tobacco plants neutralize HIV-1 BaL in TZM-bl cells with IC50 values of 0.339 μg/mL and 0.407 μg/mL, respectively[2].
VRC-01 (1-48 h) from transient tobacco plants neutralizes a panel of 10 HIV-1 Env pseudoviruses (clades A, B, C, G), while stable plant-produced VRC-01 shows slightly reduced potency against the same panel[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
ELISA, FACS, Functional assay
-
Immobilized envelope glycoprotein gp120 Protein, HIV-1 (AAC31819, HEK293, His, HY-P76390) can bind VRC-01. The EC50 for this effect is 6.987 ng/mL.
Chemical Information
-
CAS No. 1412901-55-3
-
Appearance Liquid
-
Molecular Weight 145.87 kDa
-
Color Colorless to light yellow
-
SMILES
[VRC-01]
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (260 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Boesch AW, et al. Highly parallel characterization of IgG Fc binding interactions. MAbs. 2014;6(4):915-927. [Content Brief]
[2]. Teh AY, et al. Characterization of VRC01, a potent and broadly neutralizing anti-HIV mAb, produced in transiently and stably transformed tobacco. Plant Biotechnol J. 2014;12(3):300-311. [Content Brief]
[3]. Sullivan MA, et al. Anti-idiotypic monobodies derived from a fibronectin scaffold. Biochemistry. 2013;52(10):1802-1813. [Content Brief]
[4]. Stelter S, et al. Engineering the interactions between a plant-produced HIV antibody and human Fc receptors. Plant Biotechnol J. 2020;18(2):402-414. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)